September 23, 2026
Bonus Content: Telix Drops 10% on a $1.65B All-Stock Deal. Options Can’t Help Here.
Here’s the nice thing about a free book once it’s on your computer.
The price can’t follow it there.
The book is Simple Options Trading For Beginners – options explained in plain English, written for someone starting from absolute zero.
It sells for $29.97 on my site, and most of the year that’s what it costs. Right now there’s an open window to grab it for nothing.
The moment it lands in your downloads, it’s settled. If the window closes tomorrow and the price comes back – and eventually it does – your copy doesn’t care. It’s already yours, sitting on your machine, free of whatever happens next.
That’s the whole reason to grab it today instead of “sometime.”
And if you’ve been putting off learning options because every explanation reads like a textbook – this is the one that doesn’t. No jargon. No Greeks. Just how it works, plainly.
Save your copy now, while the free window’s still open.
Good Trading,
Bill Poulos
P.S. Whatever this book costs next month, your copy stays free. That only works if you download it while the window’s open.
Telix Drops 10% on a $1.65B All-Stock Deal. Options Can’t Help Here.
Telix Pharmaceuticals did not have a quiet September. On September 11, 2026, the FDA approved Pixclara, the company’s brain-cancer imaging agent, for PET imaging to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients. The approval came after an earlier FDA Complete Response Letter and a subsequent resubmission earlier in 2026. Nine days later, on Sunday September 20, Telix announced it was buying privately held ITM Isotope Technologies Munich in a deal valued at a minimum of $1.65 billion. Following the announcement, TLX stock fell nearly 10%.
Markets don’t punish good companies for buying good assets. They punish dilution they didn’t price in, at a moment they didn’t expect it. This is not about the radiopharma sector’s strategic direction. It’s about what Telix’s shareholders woke up to on Monday morning.
The Deal in Numbers
Telix will acquire the private company for a $1.65 billion upfront payment on a cash-free, debt-free basis. The upfront structure includes approximately $1.25 billion in Telix shares, roughly $302 million in assumed net debt, and transaction expenses and other adjustments, including amounts related to management equity rollovers. On top of that, the deal includes contingent consideration of up to $700 million, payable upon achievement of specified regulatory approvals and sales milestones for ITM-11. The first milestone, $100 million, requires FDA approval of ITM-11 in GEP-NETs no later than December 31, 2027.
Upon completion, Telix shareholders are expected to own about 76.3 percent of Telix shares, while ITM shareholders are expected to own around 23.7 percent. That is the dilution that moved the stock. On H1 2026 numbers, Telix reported revenue of $477.35 million, up 22% from $390.36 million a year earlier. FY 2026 standalone guidance sits at $950 million to $970 million. Telix says ITM’s isotope business generated $273 million in 2025 revenue, and that the combined group is expected to exceed $1.3 billion in pro forma 2026 revenue and income.
What ITM Actually Brings
ITM is a leading supplier of medical radioisotopes and a major producer of non-carrier-added lutetium-177, with expanding work in actinium-225. ITM has positioned itself as a scaled producer of commercial-grade lutetium-177 and has served as a supplier into commercial radiopharmaceutical supply chains. ITM has said its isotope manufacturing business carries gross margin above 40% and is expected to deliver FY 2026 annualized EBITDA of about $106 million.
The strategic logic is supply chain sovereignty. By securing this supply chain, Telix aims to decouple its therapeutic development from reliance on third-party isotope suppliers, a move that stabilizes long-term production costs and availability. Recall that Telix’s earlier FDA rejection for Zircaix cited Form 483 observations at two third-party manufacturing and supply chain partners. Owning your isotope supply removes one category of regulatory exposure entirely.
ITM-11, ITM’s therapeutic for GEP-NETs, has positive Phase 3 data but received an FDA Complete Response Letter limited to CMC and facility inspection-related issues. That is the surprise rejection that preceded this deal. The science held; the factory did not. ITM has said ITM-11 has completed a Phase 3 trial and is also being evaluated in COMPOSE, a Phase 3 study in patients with aggressive Grade 2 or Grade 3, SSTR-positive GEP-NETs.
Sector Context: Novartis Is Not Waiting
The merger creates another well-resourced company in the radiopharmaceutical field, where Novartis remains a dominant incumbent. One widely cited industry estimate projects the radiopharmaceuticals market growing from $7.3 billion in 2025 to $8.25 billion in 2026, and to about $13.7 billion by 2030. Elsewhere in the sector, Lantheus Holdings agreed in August 2026 to be acquired by rival Curium in a deal valued at up to $8 billion. Consolidation is not a possibility at this point. It is the current state of the field.
Options Market Analysis: The Structure Problem
Here is where the analytical path ends, and honesty begins. TLX trades on Nasdaq, but its options market does not carry the liquidity that supports defined-risk structures. Open interest across strikes and expirations is thin. Bid-ask spreads are wide enough to absorb most of the edge a trader might believe they have identified.
The event risk is real and layered: shareholder approval for the share issuance is required, with an extraordinary shareholder meeting targeted for November 2026. ITM-11’s FDA resubmission timeline is binary. The Zircaix resubmission remains unconfirmed as accepted. These are three separate catalyst windows, each capable of moving the stock materially. In a name with deep options, that calendar would support a defined-risk structure around each date. In TLX, attempting to build a spread around the November vote or an ITM-11 CMC decision would likely produce wide fills and a position that costs more to enter than the expected move justifies.
For traders who believe the combined entity’s $1.3 billion pro forma revenue base is undervalued at current prices, the more executable expression is outright share exposure, sized to match the binary risk embedded in the ITM-11 regulatory clock. For traders expecting further dilution pressure or shareholder rejection, a short position in the underlying is at least achievable at a known cost. Neither is a defined-risk options strategy, but both are honest about what this market actually offers.
Risk Framework and Action Checklist
- Verify options liquidity first. Check current TLX bid-ask spreads and open interest before attempting any structure. Wide markets are a cost, not a detail.
- Mark the November shareholder vote as the first hard catalyst. Position sizing should reflect binary risk, not directional conviction alone.
- Monitor ITM-11 CMC resubmission news. An accepted resubmission is a positive catalyst. A further deficiency letter compounds the existing regulatory discount already embedded in the stock.
- Watch Novartis and Curium-Lantheus for moves in GEP-NET and lutetium-177 supply. The sector is consolidating fast enough that competitive positioning can shift before regulatory calendars resolve.
- If you believe the $1.3 billion revenue base justifies current prices post-dilution, size equity exposure to survive a second regulatory setback. TLX’s recent history shows they arrive in sequence.
